| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698955 | Clinical Oncology | 2013 | 9 Pages |
Abstract
Although similar in overall survival, chemotherapy plus vandetanib showed particular advantages over chemotherapy alone in terms of progression-free survival and overall response rate. The toxicity was comparable between the two groups. Therefore, chemotherapy plus vandetanib might be a safe and valid therapeutic option for advanced NSCLC patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yong-Ying Xiao, Ping Zhan, Dong-Mei Yuan, Hong-Bing Liu, Tang-Feng Lv, Yi Shi, Yong Song,